Novartis acquires TQJ 230, previously AKCEA-APO(a)-LRx, from Akcea Therapeutics for targeted CV therapy.

Novartis has announced that it is exercising its option to license the rights to develop and commercialize TQJ 230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy. TQJ 230 was discovered by Ionis and has been co-developed to date by Akcea and Ionis. Novartis is now responsible for worldwide development and commercialization of this asset.

Millions of people have elevated Lp(a), an independent inherited cardiovascular disease (CVD) risk factor. It is estimated that 20-30% of people who suffer from CVD have elevated Lp(a). Currently no treatment exists that specifically targets elevated Lp(a), and diet and other lifestyle changes are also not effective at reducing elevated levels.

Results of a Phase II study presented at AHA in November 2018 showed that TQJ 230 significantly reduced Lp(a) in patients with high Lp(a) and pre-existing CVD.[4] Novartis plans to conduct a Phase III cardiovascular outcomes trial with the potential of addressing the Lp(a) patient community's unmet need for effective treatment.

About Lipoprotein(a) (Lp(a)) - Lp(a) is a lipoprotein that travels through the blood. Elevated levels of Lp(a) collect in the arteries, gradually narrowing the arteries and limiting blood supply to the heart, brain, kidneys and legs. This can lead to increased risk of coronary heart disease, atherosclerosis, thrombosis and stroke.